Understanding The Shifting Patent Landscape: My Latest Podcast For The Burrill Report
April 2, 2012
While the early arrival of spring weather has many of us turning our attention to our gardends, pharmaceutical companies are facing a number of new developments in the patent landscape. In this podcast interview for The Burrill Report, I talk about Prometheus, Myriad, the compulsory license for Bayer’s Nexvar drug in India, and the status of the implementation of U.S. patent reform.
If you’ve been spending more time enjoying nature than drawing lines between laws of nature and products of nature, I’ll get you caught up in a few minutes
.
作者
相关见解
December 8, 2025
Foley Viewpoints
2026 Outlook: AI, IPOs, and the New “Normal” in Venture & Private Equity
Key Takeaways The 2026 outlook for market activity is cautiously optimistic amid ongoing challenges.Private equity firms are shifting to…
December 8, 2025
Labor & Employment Law Perspectives
Colorado Adds New NICU Leave Under FAMLI: What Employers Should Know
Colorado’s Family and Medical Leave Insurance (FAMLI) program has provided employees with paid leave for major life events since 2024,…
December 8, 2025
Labor & Employment Law Perspectives
The Post-Shutdown Compliance Crunch: Preparing for Agency Action
The longest federal government shutdown in U.S. history has ended, and employers must now refocus their attention on agency actions and…